Pan receptor interacting molecule - Takeda
Alternative Names: PRIM - TakedaLatest Information Update: 05 Dec 2023
At a glance
- Originator AB Biosciences
- Developer Takeda
- Class Anti-inflammatories; Immunotherapies; Recombinant proteins
- Mechanism of Action Fc receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 05 Dec 2023 Pan receptor interacting molecule is still in preclinical studies for Autoimmune disorders in USA (AB Biosciences pipeline, December 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 08 Jan 2019 Shire has been acquired and merged into Takeda